An Urgent Unmet Medical Need

Glioblastoma remains one of medicine's most devastating diagnoses, with nearly no meaningful survival improvement in decades. WayPath is developing PP211 to change that.

Find out more

Human Glioblastoma (GBM)

15,000+ new US cases per year; incidence rising

Less than 5% five-year survival rate

12–16 months median survival on standard of care

Temozolomide (TMZ) remains the standard — largely unchanged since 2005

No curative treatment exists for treatment-resistant or recurrent GBM

Canine Cancer

6 million new canine cancer diagnoses per year in the US

1 in 4 dogs will develop cancer in their lifetime

50% of dogs over age 10 develop cancer

Canine brain tumors closely parallel human GBM in histology and behavior

90M+ pet dogs in the US; 471M globally

THE DUAL-TRACK STRATEGY

Why Canine Trials Come First

Because canine brain tumors are biologically similar to human GBM, WayPath uses a dual-track strategy — advancing canine trials first to generate near-term data and revenue while building toward a human IND filing.

Find out more

Privacy Policy
Terms and Conditions

WayPath

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.